Skip to content

Study · Not a test of the peptide alone · 2023

4 results

In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.

González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, Barragán-Cárdenas AC, Ramírez-Celis DA, Martínez-Ramírez JA, Fierro-Medina R, García-Castañeda JE, Rivera-Monroy ZJ

Biomedical chromatography : BMC9 Sept 2023Cited by 1 (Europe PMC)

PMID37688464 (opens in a new tab)DOI10.1002/bmc.5741 (opens in a new tab)PepBankPUB-37688464
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    The sermorelin fragment (22-29) was stable to treatment with human blood and enzymes and can serve as an in-house internal standard.

    In plain wordsIn lab tests, a short sermorelin fragment resisted breakdown in blood and enzymes and could serve as a reference standard.

    Peptide
    Sermorelin
    Outcome
    No significant changeStability of Sermorelin (22-29) in blood, trypsin and chymotrypsin
    Study

    n: not reported in source

    human blood, trypsin and chymotrypsin in vitro
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Sermorelin (22-29) can be considered as in-house ISs as they were stable to enzyme and blood treatment
    1 context sentence
    Summary · context
    Treatment with human blood, trypsin and chymotrypsin was used to determine the stability of the peptides.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    GHRP-6 and the sermorelin fragment (22-29) were used as in-house internal standards to analyse a dimeric peptide in four matrices.

    In plain wordsIn lab tests, a short sermorelin fragment served as a reference standard to measure another peptide in four sample types.

    Peptide
    Sermorelin
    Outcome
    Not applicableUse of Sermorelin (22-29) as internal standard
    Study

    n: not reported in source

    human blood, trypsin and chymotrypsin in vitro
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Peptides GHRP-6 and Sermorelin (22-29) were used to analyse a dimeric peptide (26 [F] LfcinB (20-30)2 ) in four different matrices to test these peptides as in-house IS.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03LabNot a test of GHRP-6 aloneIn vitro (cell-free)Other

    In lab tests, synthesized GHRP‑6 was stable to treatment with human blood, trypsin and chymotrypsin.

    In plain wordsIn lab tests, GHRP‑6 stayed stable in human blood and with two digestive enzymes.

    Peptide
    GHRP-6
    Outcome
    Not applicableStability to enzymes and blood
    Study

    n: not reported in source

    Synthetic peptides in human blood, trypsin and chymotrypsin
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    GHRP-4, GHRP-6 and Sermorelin (22-29) can be considered as in-house ISs as they were stable to enzyme and blood treatment and can be used for the quantification of peptides in biological samples.
    1 context sentence
    Summary · context
    Treatment with human blood, trypsin and chymotrypsin was used to determine the stability of the peptides.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 04LabNot a test of GHRP-6 aloneIn vitro (cell-free)Other

    GHRP‑6 and sermorelin (22-29) were used as in-house internal standards to analyse a dimeric peptide in four matrices.

    In plain wordsIn lab tests, GHRP‑6 served as a reference standard to measure another peptide in four sample types.

    Peptide
    GHRP-6
    Outcome
    Not applicableUse as in-house internal standard
    Study

    n: not reported in source

    Synthetic peptides in human blood, trypsin and chymotrypsin
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Peptides GHRP-6 and Sermorelin (22-29) were used to analyse a dimeric peptide (26 [F] LfcinB (20-30)2 ) in four different matrices to test these peptides as in-house IS.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.